CASGEVY DIN 02552043
Status: Approved
Holder: VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
Molecule: EXAGAMGLOGENE AUTOTEMCEL
Health Canada record
| Active ingredient(s) | EXAGAMGLOGENE AUTOTEMCEL 13000000 CELLS |
|---|---|
| Dosage form | Suspension |
| Route | Intravenous |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | B06AX05 EXAGAMGLOGENE AUTOTEMCEL |
| Original market date | |
| Current status date | 23-Sep-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Vertex Pharmaceuticals (Canada) Incorporated — licence 101886, currently licensed, last inspection rating C (2024-07-30).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 34115 | 2024-09-23 | New Drug Submission (NDS) |